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Abstract 
Introduction: Cardiovascular disease (CVD) is one of the main non-communicable 
diseases globally contributing to deaths each year. Ischemic heart disease leading to 
myocardial infarction (or heart attack as it is commonly known) is one of the leading 
causes of death in the United States (Raven et al. 2008) and in South Africa (Stats 
SA, 2013). Much research is and has been done to understand the underlying 
factors that lead to this disease, but this study evaluates the role of 
phosphodiesterase 4 (PDE 4) in mediating damage or protection during an ischemic 
event. PDEs function in a coordinated manner under the instruction of various 
stimuli, mostly known to be from G-protein coupled receptors (GPCRs), in order to 
promote stimulus-specific cellular physiological effects. PDE4 was considered in this 
thesis because PDE4 exerts a dominant role in global cellular cAMP hydrolysis in rat 
cardiomyocytes (Johnson et al 2012) and is responsible for mediating 1- and 2-AR 
specific effects in normoxic cardiomyocytes (Mika et al 2014, Gregg et al 2010). This 
is through cAMP compartmentation (Nikolaev et al 2006), which might also be true 
for ischemia/reperfusion, but has never been evaluated. 
Thus the PDEs expressed in cardiomyocytes might be responsible for the 
sensitization of cardiomyocytes to ischemic damage.  
Aim: The aim was to find an alternative way to intervene during acute myocardial 
ischemia/infarction, through the GPCR pathways by evaluating the role of 
phosphodiesterase 4 (PDE 4) in mediating damage or protection during an ischemic 
event. 
Methods: Cardiomyocytes were isolated from adult male Wistar rat hearts and 
cultured overnight on 100ug/ml laminin / entactin (L / E). Following overnight cultures 
at 5%CO2 and 37°C, experiments were done in modified medium X culture buffer 
(MMXCB) with different treatment conditions of rolipram (a PDE4 inhibitor), 
dobutamine (b1AR-agonist), formoterol (b2AR-agonist), isoproterenol (b1- and 
b2AR-agonist), HU210 (synthetic cannabinoid) and THC (delta-9 
tetrahydrocannabinol) to compare adult rat cardiomyocytes (ARCM) attachment, 
contracture and viability. Cardiomyocytes cultured on L/E were subjected to 20 
minutes of simulated ischemia [using MMXCB that contained 3mM 2-deoxyglucose 
(2DG) and 10mM Sodium dithionite (SDT)] with the different treatment drugs 
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administered during ischemia, followed by 15 minutes reperfusion. Cell viability was 
determined by staining cells with JC-1 and images of cells in a field view that was 
captured using fluorescence microscopy. The cells were analysed according to cell 
length, morphology and fluorescence intensity with the help of ImageJ Fiji (open 
source software at http://fiji.sc/Fiji). 
Results: A Significant difference in the cell length parameter was observed between 
the normoxic untreated groups compared to the ischemic untreated groups and this 
indicated that the ischemic conditions were sufficient to result in hypercontracture 
induced by ischemia/reperfusion. Regardless of eliciting a proper ischemic insult, no 
treatments administered during ischemia could alter hyper contracture in the 
cardiomyocytes. 
Mitochondrial viability, measured in red over green fluorescence intensity did not 
always portray a significant difference between the normoxic untreated and ischemic 
untreated groups. The mitochondrial viability did however increase significantly when 
10nM HU210 was administered during ischemia compared to ischemia untreated 
group. 10uM THC increase the viability when compared to ischemia untreated. With 
the following experiments the results could not be obtained. 
The rod-shaped ARCMs attachment  as measured by percentage cell viability 
according to morphology, did show a significant decrease after ischemic stimulation, 
but no differences could be monitored when the different treatment conditions was 
compared as the percentage viability decreased greatly to levels of 20% and less. 
Conclusion: This study suggests that B-AR pathways did not have an effect on 
cardiomyocyte hyper contracture during an severe ischemia insult, nor insulin. It did 
show that the cannabinoid-receptors increased mitochondrial viability during 
ischemia and does indeed play a role during ischemia/reperfusion. However, the 
exact mechanisms for these effects seen are unknown and need further 
investigation. PDE4 inhibition with and without different agonists also failed to alter 
hypercontracture. This lack of change in cardiomyocyte survival parameters in 
response to the different protective and damaging drugs is considered to be a result 
of the harsh ischemic conditions used. It is recommended to instead incorporate 
hypoxia with these treatments to evaluate the effects of PDE4 in the presence and 
absence of b-AR, cannabinoid and insulin signalling. 
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Opsomming  
Inleiding: Kardiovaskulêre siekte is een van die grootste nie-oordraagbare siektes 
wat wêreldwyd bydra tot talle sterftes elke jaar. Iskemiese hartsiekte wat tot 
miokardiale infarksie (hartaanval, soos dit algemeen bekend staan) lei, is een van 
die grootste oorsake van sterftegevalle in die Verenigde State van Amerika (Raven 
et al. 2008) asook in Suid-Afrika (Stats SA, 2013). Baie navorsing is reeds en word 
tans gedoen om die onderliggende faktore wat tot hierdie siekte lei te verstaan. 
Hierdie studie evalueer die rol van die ensiem, fosfodiesterase 4 (PDE4) in 
miokardiale iskemie. Fosfodiesterases funksioneer in 'n gekoördineerde wyse in 
opdrag van verskeie stimuli, via G-protein gekoppelde reseptore (GPCRs), om 
sodoende stimulus-spesifieke sellulêre fisiologiese effekte teweeg te bring. Daar is 
op PDE-4 in hierdie tesis gefokus, vanweë sy dominante rol in die globale sellulêre 
cAMP hidrolise in rot kardiomiosiete (Johnson et al 2012). Dit is verantwoordelik vir 
die bemiddeling van b1- en b2-adrenergiese reseptor (AR) spesifieke effekte in 
normoksies kardiomiosiete (Mika et al 2014, Gregg et al 2010), deur middel van 
sikliese nukleotied (cAMP) kompartementalisering (Nikolaev et al 2006), wat 
moontlik ook vir iskemie / reperfusie geld, maar nog nie getoets is nie. Dit is dus 
moontlik dat die PDEs wat in kardiomiosiete voorkom, verantwoordelik is vir die 
sensitisering van kardiomiosiete tydens iskemie. 
Doel: Om 'n alternatiewe manier te vind, deur middel van G-proteïen gekoppelde 
reseptore (GPCR’s), te om die rol van PDE 4 in miokardiale beskadiging of 
beskerming tydens iskemie te evalueer.  
Metodes: kardiomiosiete is uit volwasse manlike Wistar rotharte geïsoleer en oornag 
op 100ug / ml laminin / Entactin (L / E) gekweek. Na oornag inkubasie met 5% CO2 
by 37 °C, is die selle in gemodifiseerde medium X kultuur buffer (MMXCB) 
blootgestel aan behandeling met verskillende middles soos rolipram, dobutamien, 
formoterol, isoproterenol, HU210 en THC en die effekte op volwasse rot 
kardiomiosiet (VRKM) vashegting, kontraktuur en lewensvatbaarheid vergelyk. Die 
kardiomiosiete gekweek op L / E, is aan 20 minute van gesimuleerde iskemie 
(MMXCB plus 3mM 2DG en 10mm SDT) blootgestel in teenwoordigheid van 
bogenoemde middels, met die verskillende behandeling dwelms toegedien tydens 
iskemie, gevolg deur 15 minute reperfusie. Die lewensvatbaarheid van selle is 
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bepaal deur kleuring met JC-1 en fluoressensie mikroskopie. Die selle is ontleed 
volgens lengte, morfologie en fluoressensie intensiteit met die hulp van Image J Fiji 
(Ope toegang tot sagteware deur http://fiji.sc/Fiji). 
Resultate:'n Beduidende verskil in sellengte is gevind tussen die normoksiese 
onbehandelde groepe vergeleke met die iskemiese onbehandelde groepe wat toon 
dat die iskemiese toestande genoeg was om tot behoorlike beskadiging te lei, soos 
angedui deur die kontraktuur van die selle. Ongeag hierdie beskadiging, het 
geeneen van die ander middels toegedien tydens iskemie, enige effek op sellengte 
gehad nie.  
Mitokondriale lewensvatbaarheid, is gemeet in rooi oor groen fluoressensie 
intensiteit en het nie altyd 'n beduidende verskil tussen die normoksiese 
onbehandelde en iskemiese onbehandelde groepe getoon nie. Die mitokondriale 
lewensvatbaarheid het egter aansienlik verhoog tydens toediening van 10nM HU210 
tydens iskemie in vergelyking in vergelyking met die iskemie onbehandelde groep. 
Dieselfde is gevind toe isoproterenol in kombinasie met rolipram tydens iskemie 
toegedien is. Daarenteen het 10uM THC die mitokondriale lewensvatbaarheid 
grootliks verminder in vergelyking met onbehandelde iskemie. Laasgenoemde 
eksperiment kon egter nie by herhaling dieselfde resultate lewer nie. 
Die staafvormige VRKMs vashegting is gemeet deur lewensvatbaarheid persentasie 
van sel soos aangedui deur morfologie, en het 'n beduidende afname na blootstelling 
aan iskemie getoon. Geen verskille is egter waargeneem tydens blootstelling aan die 
verskillende middels nie.  
Gevolgtrekking: Hierdie studie dui daarop dat die beta-adrenergiese paaie nie 'n 
effek op kardiomiosiete hiperkontraksie tydens 'n iskemiese insident het nie. Dit het 
wel getoon dat kannaboïed-reseptor stimulasie, ‘n toename in mitokondriale 
lewensvatbaarheid tydens iskemie teweegbring en moontlik 'n rol tydens iskemie / 
reperfusie speel. Die presiese meganismes vir die effekte wat waargeneem was, is 
egter nog onbekend en benodig verdere ondersoek. PDE-4 inhibisie met en sonder 
verskillende agoniste het ook geen effek op kontraktuur gehad nie. Die gebrek aan 
verandering in kardiomiosiet oorlewingparameters in hul reaksie op die verskillende 
beskermende en skadelike middels, kan moontlik aan die erge iskemie waaraan die 
selle blootgestel is, toegeskryf word. Dit word aanbeveel om die selle aan hipoksie 
(liewer as iskemie) bloot te stel ten einde die effek van die middels te herevalueer.  
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Chapter 1: Literature review 
Introduction 
Cardiovascular diseases are one of the main non-communicable diseases globally 
contributing to deaths each year (WHO, 2011). Much research is and has been done 
to understand the underlying factors that lead to this disease. Most cardiovascular 
diseases can be prevented or reduced by maintaining a healthy well balanced 
lifestyle. However there are still millions of people that suffer from some form of 
cardiovascular diseases (Raven et al, 2008). Most of these conditions are caused by 
arteriole problems for example; a blockage in an artery or an artery wall that has 
been ruptured. Heart attacks, Angina pectoris, Strokes and Atherosclerosis are all 
common forms of cardiovascular diseases (Raven et al. 2008).  
 
Ischemic heart disease leading to myocardial infarction (or heart attack as it is 
commonly known) is one of the leading causes of death in the United States, and 
account for one-fifth of all deaths in the United States (Raven et al. 2008), a 
phenomenon which is also seen in white South Africans (accounts for 11.1% deaths 
in this population group) in 2013 (Stats SA, 2013). Myocardial infarction, results from 
an insufficient supply of blood to a certain small area or even a bigger area of the 
heart muscle. This causes the myocardial cells in these areas to die of oxygen and 
nutrient deprivation, waste and metabolite product accumulation and ion imbalances.  
 
The myocardial cells are better known as contractile and non-contractile 
cardiomyocytes in the research field. Some of the cells are responsible for 
generating contractile force in the intact heart and others form the cardiac conduction 
system, which is responsible for the control of the rhythmic beating of the heart 
(Woodcock et al, 2005). In this thesis cardiomyocytes will refer to contractile 
cardiomyocytes isolated from the ventricles. 
 
Physiology is the study of the functioning of living things (Sherwood, 2010). 
Maintaining homeostasis is essential for the survival and normal functioning of cells. 
Each cell has its own special activities that contribute as an integral part of a system 
to maintain homeostasis, and this is the foundation of physiology (Sherwood, 2010). 
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A brief but insightful physiological background will be given regarding the reason for 
the research project. This project was developed to gain answers to some of the 
many questions around the common cardiovascular event: Myocardial infarction 
(MI). 
The aim is to find an alternative way to intervene during MI, through g-protein 
coupled receptor (GPCR) pathways, since the prevention or reduction of risk is 
already well researched. With the understanding of an ischemic event within the 
heart cells, this thesis also evaluates the role of phosphodiesterase 4 (PDE 4) in 
mediating damage or protection during an ischemic event.  
 
Ischemic damage can be enhanced through beta-adrenergic receptor 1 (Spear et al, 
2007), while protection can be elicited through beta-adrenergic receptor 2 (Chesley 
et al, 2000) as well as through cannabinoids (Shmist et al 2006,Durst et al, 2007) 
and insulin(Abdallah et al, 2006; Jonassen et al, 2001; Zhang et al, 2005). The 
usage of freshly isolated cardiomyocytes that were cultured for 1 day was 
incorporated during this investigation. A background of each of these components 
will be discussed and presented in the following pages. 
 
Function of the heart 
Normal condition 
Normal function of the heart will briefly be discussed followed by how pathology 
occurs during ischemia and reperfusion therapy. The heart is one of the main 
components that compromise the circulatory system. Another two components are 
the blood vessels and blood. This system is responsible for the continuous 
movement of all body fluids (Young et al, 2010), example blood plasma, interstitial 
fluid and lymph. Its primary functions are the transportation of oxygen (O2) and 
nutrients to the different tissues, and also the removal of carbon dioxide (CO2) and 
metabolic waste products from the different tissues (Sherwood, 2010). It also plays a 
role in temperature regulation and the distribution of signalling molecules or cells. 
Thus in short the circulatory system contributes to maintaining homeostasis through 
the transportation of O2, CO2, waste, electrolytes and hormones from one area of the 
body to another (Sherwood, 2010). 
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Cardiomyocytes are the cells responsible for generating contractile force in the intact 
heart in response to electrical currents from the SA node. Specialized non-contractile 
cardiomyocytes that form the cardiac conduction system are responsible for control 
of rhythmic beating of the heart (Raven et al. 2008).  
 
More than 40% of the cardiomyocyte cell volume contains mitochondria, the energy 
generating organelles. Mitochondria are very dependent on O2 for energy production 
and this means the contractile cardiomyocytes depend on aerobic metabolism. The 
heart’s primary fuel substrates are fatty acids and to a much lesser degree, glucose 
and lactate, but this is only during normal aerobic conditions. The heart is very 
adaptable and can thus shift into many metabolic pathways to gain nutrients. 
However pathologies arise when blood flow is restricted, this is not only due to 
insufficient nutrients, but also largely due to insufficient O2 supply (Opie, 2004). This 
leads to cellular acidosis, ion imbalances, metabolite and waste product 
accumulation and cellular damage. 
 
Ischemia and reperfusion pathologies 
Ischemia, which is the deprivation of blood supply to an organ, has long been 
recognized as a critical factor in the clinical outcome of haemorrhagic shock, stroke, 
organ transplantation and myocardial infarction (Eltzschig et al, 2004). 
As soon as the heart cells are challenged with a state of deprived O2 the energy 
metabolism is switched to anaerobic metabolism (Raven et al. 2008), but heart cells 
cannot generate enough adenosine triphosphate (ATP) through anaerobic 
metabolism. This leads to a decrease in the energy levels within the heart cells, 
which in turn cause a build-up of ions such as calcium, hydrogen and sodium within 
the heart cells. The energy depletion and ion imbalances then lead to tissue 
damage. 
The cellular effects caused by ischemia or hypoxia include; cellular acidosis, altered 
membrane potential, an alteration in the ion distribution, cellular swelling, 
cytoskeletal disorganization, decreased ATP and contracture (Eltzschig et al, 2004). 
The damage is worsened by an increased release of adrenaline and noradrenaline 
that cause beta-adrenergic receptor activation. This in turn favours cyclic AMP 
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production and thus activates the PKA-pathway, which is implicated in cell damage 
and death during ischemia. 
Reperfusion, which refers to the re-establishment of blood flow in the ischemic 
tissue, enhances ischemic pathologies due to the rapid reintroduction of oxygen, 
ATP production and return to alkalinity of the intracellular fluid. The latter contribute 
to opening of the mitochondrial permeability transition pore, which dissipates the 
mitochondrial membrane potential and acts as a stimulus of apoptosis (Haunstetter 
et al, 1998). Hypercontracture is triggered by the excessive contractile activity of 
Ca2+ oscillations due to reperfusion. Hypercontracture also disrupts the cellular 
architecture leading to sarcolemmal rupture and cardiomyocyte death (Garcia-
Dorado et al, 2014; Buja, 2005; Rodriguez-Sinovas et al, 2007). 
 
Models of ischemia/reperfusion in cardiovascular research 
In the cardiovascular research setting, ischemia/reperfusion is induced or simulated 
with a variety of methods to investigate the cause and effect of this disease state. 
Researchers try to find new methods of actions for intervention and prevention of this 
malfunction, such research is mainly conducted on animal hearts like rats and mice. 
These studies usually focus on whole heart/organ research or cellular research (Diaz 
et al, 2006). 
Whole heart 
In the event of conducting research on whole hearts, one of three protocols is used 
to induce ischemia: global, regional or low flow ischemia. Global ischemia is applied 
through deprivation of O2 and nutrients throughout the entire heart by stopping 
delivery of oxygenated nutrient buffer to the heart (Ostádal et al, 1991).Regional 
ischemia is induced by blocking off the coronary artery with a silk suture, which then 
causes the deprivation of O2 and nutrients in that area and then upon reperfusion 
causes myocardial infarction (Ostádal et al, 1991). 
 Low flow ischemia is induced when the fluid is pumped through the heart at a very 
slow but constant rate to thus simulate a partial blockage. Whole heart perfusions 
are usually elicited with the Langendorff’s with/or working-heart perfusion 
techniques. Parameters that can be measured include total work heart mechanical 
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functions of functional recovery and tissue sections that can be probed for various 
signalling proteins (Webster et al, 2014). 
Cardiomyocyte 
Cellular research is very different to that done on whole hearts. Ischemia is 
simulated or induced through buffers or methods specified for specific cells; this 
would include: pelleting of cells and adding an oil layer on top, applying an ischemic 
buffer and/or a hypoxic gas. 
Simulated ischemia 
The buffers used to induce or simulate ischemia would contain normoxic buffer, 
where glucose and HEPES are reduced or omitted, pH reduced to 6.0-6.4,and 
supplemented with lactate, 2-deoxyglucose (2-DG) and Sodium hydrosulfite (Sodium 
dithionite) . 2-DG is a glucose analogue that cannot be metabolized; a very well-
known inhibitor of glycolysis and a competitive inhibitor of glucose transport 
(Vijayaraghavan et al, 2006). It interferes with the cellular mechanisms by competing 
with glucose for the key enzymes associated with glycolysis (Lazlo et al, 1961). 
Sodium dithionite (Na2S2O4) is an O2 scavenger (Egar et al 2014) and a powerful 
reducing agent. It is used to create anaerobic conditions in vitro (Archer et al, 1995). 
It removes all traces of O2 in the buffer solutions (Bright et al, 1992). 
Hypoxia conditions through pelleting 
This is done by centrifuging freshly isolated cardiomyocytes into a pellet with only a 
thin layer of supernatant that is then covered by oil, which has proven to be an 
excellent model of simulated ischemia (Diaz et al, 2006).The reason behind this 
conclusion is that pelleting causes an increased metabolite build-up in an enclosed 
space. Metabolic inhibition occurs naturally through the build-up of lactate and H+ 
and exhaustion of available metabolic substrates, this then avoids using exogenous 
metabolic inhibitors (Diaz et al, 2006). 
Hypoxia with gas 
Severe hypoxia can be induced by using modular incubator chambers with nitrogen 
concentrations between 95% and 100%.This has been used to elicit hypoxia on the 
cultured cardiomyocytes in this study. The modular hypoxic incubator chamber has 
an air tight seal and the cardiomyocyte cultured plates are placed inside this 
chamber. The O2 is then replaced by nitrogen gas to subject the cardiomyocytes to a 
hypoxic event. Additional modifications to the experimental buffer are sometimes 
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also made, for example the addition of lactate and 2-DG, as well as a reduction in pH 
to 6.0-6.4. 
After simulating ischemia, reperfusion is replicated by adding well oxygenated media 
of normal ionic composition, normal physiological pH and proper temperature to the 
cells. Reperfusion contributes to myocardial cell damage through lethal necrosis of 
cardiomyocytes. This damaged caused by reperfusion is termed “reperfusion injury”. 
Reperfusion injury starts within the first few minutes of reperfusion in cardiomyocytes 
and then causes hyper contracture development in the cardiomyocytes (Abdallah et 
al, 2006). 
 
Parameters that can be measured include cell length as an indication of contracture 
or hypercontracture, viability through cell morphology or cell stains for intracellular 
signalling or cell viability assessment for example mitochondrial viability. 
Through understanding these pathways, one can develop new methods of 
intervention and treatment to reduce cell death during reperfusion. 
 
Different cell death mechanisms during Ischemia 
In acute myocardial ischemia of a proper and sufficient duration that causes 
substantial injury in all the models of ischemia research, the substantial majority of 
cell death (which is 90%) happens through oncosis (Diaz et al, 2006).Oncosis is 
derived from the Greek word “onkos”, which means swelling (Diaz et al, 2006). 
During oncosis there is cytoplasmic swelling with intracellular organelles swelling, 
causing increased cell membrane permeability, blebbing and ultimate cell membrane 
rupture. Necrosis is an example of oncosis, where cell membranes are ruptured due 
to unorganized cell death independant of ATP and allow hydrophilic dyes such as 
trypan blue to enter the necrotic cell cytosol. Consequently necrotic cell stain blue 
while uncompromised cells don’t take up the dye. 
 
Some pathological conditions can cause cardiomyocytes to undergo apoptotic and 
necrotic responses. Signalling pathways involved in apoptotic responses in 
cardiomyocytes have been investigated in cell models in both the extrinsic and 
intrinsic pathways. These signalling responses are most readily observed, following 
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brief periods of ischemia in vivo or simulated ischemia in isolated cells (Woodcock, 
E.A. et al, 2005). Apoptosis is a well-organized cell death dependent on ATP, and 
thought to be enhanced by the availability of ATP during reperfusion (Dispersyn et al, 
2001). In apoptosis, the cell cytosol shrinks; there is a marked chromatin 
condensation and the cells split into small apoptotic bodies that can be removed by 
neighbouring cells. Apoptotic cells can be detected by fluorescence intensity through 
JC-1 staining. This is used to test the mitochondrial membrane potential. If the JC-1 
stain fluorescence red the cells are still viable, but as soon as the cells fluorescence 
green, the cells are in the apoptotic fate. 
 
The use of cardiomyocytes in research 
Experimentation with freshly isolated cardiac myocytes can allow us to gain 
knowledge of the cardiovascular system on a molecular basis. The isolation of a high 
quality yield of cardiac myocytes is the most important factor for a successful 
experiment. Isolated cardiomyocytes have been used for more than two decades in 
the research setting, to study the effect of ischemia. The enzymatic separation of 
cardiomyocytes can be done with a variety of different protocols. The key elements 
to isolating cardiomyocytes are using a Langendorff perfusion system with calcium-
free media. This is a very delicate procedure and any changes in the collagenase, 
protease or trypsin activity or the time of perfusion can lead to a decrease or 
increase in the percentage viability yield of cardiomyocytes. Good cardiomyocyte 
isolation will yield 70% to 80% or even more rod-shaped viable cells with clear visible 
striations when viewed under the light microscope (Diaz et al, 2006). 
 
The isolated cardiomyocytes can be cultured overnight or for a few days, which 
allows the possibility of genetic manipulation to precisely target the molecular 
machinery during ischemic events, and opens up exciting possibilities to gain further 
knowledge in this field. Uses for cardiomyocytes include studying cell volume 
regulation in ischemia; manipulating gene expression in cardiomyocytes to study 
ischemia and probing the role of mitochondria in ischemia in intact cardiomyocytes. 
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Advantages and disadvantages of isolated cardiomyocyte research 
The most obvious advantage of cardiomyocyte research compared to whole heart 
research is the elimination of other cell types like endothelial cells and fibroblasts 
(Diaz et al, 2006). This means that the researchers can for instance only work with 
the mitochondria of the cardiomyocytes, since it is a pure collection of 
cardiomyocytes. Working with cardiomyocytes also gives the researcher the 
opportunity to study the cells visually much better through microscopy. 
The disadvantage of using cardiomyocytes is losing the extracellular matrix and 
other neighbouring cells which results in not having the same response as in the 
entire heart for instance. The cardiomyocytes are also more prone to infections 
during experiments than in the whole heart experiments because they are kept for 
longer, so greater caution should be used during experimentation of cardiomyocytes. 
 
B-Adrenergic receptors 
Beta-adrenoceptors (β-AR), β1-, β2- and β3-ARs are found in the heart, although β1 is 
documented as the most prominent β-AR in the human heart (Brodde, et al 2006). 
The ratio of β1 to β2 adrenoceptors are about 4 to 1 in the ventricles (Brodde et al, 
2006). Norepinephrine is a neurotransmitter that is released from the sympathetic 
adrenergic nerves, and binds to these receptors at the cardiomyocyte membrane 
(Thackeray et al 2012).The β1 and β2 –adrenergic receptors both work through the 
coupling of G-stimulatory (Gs) protein that activates adenylyl cyclase (AC), but β2 
along with β3 can also couple to G-inhibitory (Gi) proteins. 
As can be visualized by referring to figure 1, beta-adrenoceptors are coupled to Gs, 
which activate AC to increase cyclic AMP (cAMP).This then activate cAMP-
dependent protein kinase A (PKA) that phosphorylates the L-type calcium channels, 
which increase calcium entry into the cardiomyocytes during action potentials. An 
increase in calcium entry leads to enhanced release of calcium by the sarcoplasmic 
reticulum. PKA phosphorylates sites on ryanodine receptor at the sarcoplasmic 
reticulum, which further enhances the release of calcium through the ryanodine 
receptors. This provides more calcium for binding the troponin-C, which enhances 
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contraction (inotropy). PKA can also phosphorylate myosin light chains; which 
contribute to the positive inotropic effect of beta-adrenoceptor stimulation. PKA-
mediated phosphorylation of phospholamban lifts the inhibitory effect of 
phospholamban on sarcoplasmic- and endoplasmic reticulum calcium ATPase 
(SERCA). This allows SERCA to pump calcium faster back into the sarcoplasmic 
reticulum to enhance cardiomyocyte relaxation during diastole (lusitropy).The cardiac 
effects of β1- and β2-ARs result in positive inotropy, chronotropy (increased heart 
rate) and dromotropy (increased rate of conduction velocity), while only β1-ARs 
induces lusitropy. The coupling ofβ2- and β3-AR isoforms to Gi provides a balance in 
-AR signalling by reducing the cAMP production (Thackerayet al. 2012), as 
illustrated below in Figure 1.1. 
 
 
 
During an ischemic event overstimulation of B-AR occur, in response to a large and 
progressive release of the catecholamines from the adrenergic nerve terminals (Yu, 
Q. et al, 2008). This causes an enormous threshold activation of the β-adrenoceptors 
and a large release of cAMP, which can then further accelerate the ischemia induced 
Figure 1.1: Beta-Signalling and cAMP, the signalling events after beta-adrenergic receptor 
activation 
Abbreviations 
B-AR:  beta-adrenergic receptor AC:  Adenylyl Cyclase   Gs: G-stimulatory protein  
Gi:  G-inhibitory protein  PKA:  cAMP-dependant protein kinase A  SR: Sarcoplasmic Reticulum 
Ca
2+
: Calcium 
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cell damage within the cardiomyocytes (Yu, Q. et al, 2008). This is partly because 
the induction of inotropy during ischemia promotes ATP consumption and 
intracellular calcium accumulation that promotes contracture and cell death. 
 
In the research setting, β-adrenoceptor agonists and antagonists are used to study 
and identify the possible mechanism involved in the cAMP/PKA pathways. 
Dobutamine is used as a β1-AR agonist (Chou et al, 2012), formoterol is used as a 
β2-AR agonist (Jesinkey, 2014) and BRL37344 is a β3-agonist (García-Prieto et al 
2014).Cardiac βAR stimulation in the rat cardiomyocytes, can affect apoptosis with 
β1-AR via the Gs-protein and induce pro-apoptotic effects, while the β2-AR via the 
Gi-protein, induces anti-apoptotic effects in the hypertrophic heart (Brodde et al, 
2006) and in the ischemic heart (Spear et al, 2007;Chesley et al, 2000). 
 
cAMP and cGMP signalling pathways 
Cyclic AMP and cyclic GMP are second messengers involved in regulating a vast 
number of processes, such as cardiac function. cAMP influences growth, movement 
and differentiation in cells. cAMP also influences the vasculature: relaxation and 
contraction, movement, shape, proliferation and response (especially to vascular 
trauma and hypoxia) of the blood vessel smooth muscle cells (VSMC’s). In 
cardiomyocytes this second messenger also influences the heart rate (chronotropic) 
and contractility (inotropic) actions as well as apoptosis and hypertrophy. Thus cAMP 
plays a regulating role in the strength and frequency of cardiac relaxation and 
contraction. The stimulation of adenylyl cyclases via GPCRs by catecholamines 
generates cAMP which mainly target PKA. Other targets for cAMP include: the 
exchange factor for Rap, Epac and cyclic nucleotide-gated ion channels (Bos, 2006).  
The stimulation of guanylyl cyclases (GC) in response to natriuretic peptides and 
nitric oxides (NO) generates cGMP. In turn cGMP activates its downstream effectors, 
which include protein kinase G (PKG) and cyclic nucleotide-gated channels. cGMP 
also regulate inotropy and metabolic responses in cells. 
By their generation and activation of downstream effectors, one can notice that 
cGMP and cAMP pathways can often have opposing influences on the cardiac 
function. There is cross-talk between these two signalling pathways through the 
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activity of cyclic nucleotide-degrading enzymes, which are better known as 
phoshodiesterases (PDEs). PDEs have been shown to play a role in directing the 
fate of cardiomyocytes in the context of anoxia, where ATP loss and contracture was 
enhanced by general inhibition of all PDEs with IBMX (Geisbuhler et al 2001). 
 
Phosphodiesterases 
PDE’s are a class of enzymes that hydrolyse the cellular cyclic nucleotides cAMP 
and cGMP to their inactive form (Figure 1.2) and therefore play an essential role in 
the cyclic nucleotide cellular response pathways. As PDEs is the only enzymes 
controlling the degradation of cAMP, they are considered a very important 
component of the normal physiological function of most systems within the body, 
including in the heart. They are the key role players to ensure selective activation of 
different pathways in order to mediate selective GPCR functions in the heart. PDEs 
coordinate such physiological complexities through the compartmentalization of 
cyclic nucleotides within heart cells (Figure 1.3). 
 
 
 
  
Figure 1.2cAMP breakdown: Showing cAMP breakdown with PDE4 
Abbreviations 
B-AR: beta-adrenergic receptor AC: Adenylyl Cyclase   Gs: G-stimulatory protein
  
Gi: G-inhibitory protein  PKA: cAMP-dependant protein kinase A  PDE4: Phosphodiesterase 4 
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There are eleven families of PDE’s identified (PDE1-PDE11), each with their own 
distinctive characteristics. They are found in different tissues, of which 7 families are 
found in the heart, while five PDE families have been studied in the heart. cAMP is 
hydrolyzed in the heart by four PDE’s: PDE1, PDE2, PDE3 and PDE4. PDE1 is 
activated by Ca2+ / calmodulin (CaM) and can also hydrolyze cGMP. PDE2 is 
stimulated by cGMP and can also hydrolyze cGMP.PDE3 is inhibited by cGMP while 
PDE4 is specific for cAMP and insensitive to cGMP (Fischmeister et al. 2006). In 
mouse cardiomyocytes, it has been shown that PDE8 modulates cAMP signalling 
(Patrucco et al, 2010). PDE3 and PDE4 are the most abundant and major 
contributors of cAMP-hydrolysis in rodent cardiomyocytes (Richter et al, 2011). 
 
PDE 4 in cardiac function 
One of the main PDE’s expressed in the heart is PDE4 (Fu et al, 2013), where it 
regulates global cAMP levels in cardiac cells. PDE4 is predominantly activated 
through β-AR stimulation and thereby shapes the compartments of cAMP produced 
by-AR and its physiological effects. The PDE4 family consist of 4 genes PDE4A, 
PDE4B, PDE4C and PDE4D that give rise to multiple isoforms. Only the PDE4A, 
PDE4B and PDE4D genes are expressed in cardiac tissue, and are localized to 
specific regions within the cardiomyocytes (Figure 1.3). These regions include the 
sarcoplasmic reticulum and Z-discs, where they are likely to influence cAMP and 
cGMP signalling to the end effectors of contractility (Roa, 2009).Different PDE4 
isoforms control the PKA-mediated regulation of 1- and 2-ARs, and are said to be 
anchored to the L-type calcium channels (LTCC), cardiac ryanodine receptors 
(RyR2), the phospholamban / sarcoplasmic reticulum calcium ATPase (PLB/SERCA) 
complex and troponin I (Richter et al, 2011).  
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As early as the 1970’s an interest arose regarding the cardiovascular effects of PDE 
inhibitor drugs for especially chronic heart failure (Feneck, 2007) and there is still 
significant interest in the potential of PDE inhibitors in the treatment of 
cardiomyopathy. Yuan James Rao and Lei XI stated that it seems PDE-inhibitors 
hold a great promise as clinically applicable agents. By this they say that it could 
improve cardiac performance and cell survival under critical situations. Ischemic 
heart attacks, heart failure and cardiopulmonary bypass surgery are some examples 
of the critical situations. 
 
Although much research has been done on the possible therapeutic role of PDEs 
during cardiac pathology, most of the focus has been on hypertrophy and heart 
failure, while the role of PDEs in ischemia has been neglected.PDE4 is considered 
one of the most important key players in the control of cAMP compartmentalization 
from b-ARs, yet the role of PDE4 in b1-AR mediated damage and b2-AR induced 
protection has never been evaluated. The inhibition of PDE4 by roflumilast have 
Figure 1.3: Localization of PDE4 in the cardiomyocyte. 
Abbreviations 
B-AR: beta-adrenergic receptor AC: Adenylyl Cyclase   Gs: G-stimulatory protein  
Gi: G-inhibitory protein  PKA: cAMP-dependant protein kinase A  PDE4: Phosphodiesterase 4 
SR: Sarcoplasmic reticulum  Ca
2+
: Calcium    PLB: Phospholamban 
LTCC: L-type calcium channel  SERCA: sarcoplasmic- and endoplasmic reticulum calcium ATPase 
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been proposed (Kwak et al 2007) to have potential for protecting cardiomyocytes 
during ischemia/reperfusion. However, these authors made this deduction based on 
a model of nitric oxide-induced apoptosis, and a closer model to 
ischemia/reperfusion (I/R) is necessary for such a deduction. There are no 
publications that evaluated the role of PDE4 during I/R, which is what was aimed by 
this thesis. 
Insulin signalling in cardiomyocytes 
Experimental and clinical studies have shown that the administration of insulin during 
reperfusion is cardio protective (Abdallah et al, 2006; Heng et al, 1977). Several 
studies and experiments have been done to determine whether insulin has a 
protective effect against myocardial reperfusion injury. In the late 1960s insulin was 
found to have protective properties when it was found to have a reduced-in-hospital 
mortality risk rate, when patients were treated with a glucose-insulin-potassium 
scheme (GIK), after experiencing an acute myocardial infarction (Sodi-Pallares et al, 
1962). Dysfunction and defects of SERCA has been reported in ischemia/reperfusion 
myocardium (Yu et al, 2008), which led to decreased myocardial contractility and 
reduced removal of intracellular calcium. Yu et al (2008) found that insulin promoted 
SERCA activity and thereby increasing the re-uptake of Ca2+ through the SR. In a 
study by Rao et al (1997), they found with insulin treatment a reduction in 
extracellular lactate release after ischemia and after reperfusion. Insulin treatment 
improved the transition from anaerobic to aerobic metabolism, and resulted in 
improved cellular survival after ischemia/reperfusion (Rao et al, 1998). 
 
Insulin-mediated glucose uptake is another important mechanism through which 
insulin induces cardio protection to the whole heart and cardiomyocytes (Heng et al, 
1977). Insulin–mediated glucose uptake under normoxic conditions has been shown 
to be dependent on the activity of certain PDE3 and 4. In primary rat adipocytes the 
inhibition of PDE3B respectively with milrinone and OPC3911 reduced glucose 
uptake induced by insulin (Zmuda-Trzebiatowska et al 2005). PDE4 inhibition in 
whole heart perfusions was found to reduce insulin-mediated glucose uptake 
(Imahashi et al 2001). What make this especially interesting is that the insulin 
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receptor is a tyrosine kinase receptor and not a GPCR, yet it mediates its effects 
through PDEs. This might possibly be through the regulatory effects that kinases 
such as PKB, ERK and PKA have on PDEs (Omori, 2007). More noteworthy is the 
role that PDE4 plays in both b-AR signalling and insulin signalling, and therefore it is 
necessary to evaluate the role of PDE4 in insulin-mediated cardio protection. 
Cannabinoids 
Cannabis sativa L. has a long history as a medical plant and was fundamental in the 
discovery of the endocannabinoid system (ECS). Within our bodies, the ECS is 
considered a complex lipid signalling network, which comprises the classical 
cannabinoid receptors: type-1 cannabinoid (CB-1) receptor and type-2 cannabinoid 
(CB-2) receptor. The CB1 and CB2 receptors and endocannabinoid degrading 
enzymes are present in cardiovascular tissues (Patcher, 2008). In the ECS, different 
proteins play distinct roles in the control of numerous physiological and 
pathophysiological processes. 
Endocannabinoids are cannabinoids that are naturally synthesized within the body. 
The natural two most studied endocannabinoids are anandamide also known as 
arachidonoyl ethanolamide (AEA) and 2-arachidonylglycerol (2-AG). 
Phytocannabinoids are cannabinoids which are natural plant-derived products and 
are capable of either directly interacting with the CB1/CB2 receptors or share 
chemical similarities with the endocannabinoids.CB1 and CB2 receptors are GPCRs 
that largely couple to Gi to produce cGMP and nitric oxide. The discovery of the 
cannabinoids as a whole came mainly from the marijuana plants which are also 
better known as cannabis L sativa plants. The psychoactive component, THC was 
one of the first studied cannabinoids. 
 
Cardio protection by Endocannabinoids and Phytocannabinoids 
Studies with endocannabinoids and phytocannabinoids proved that the cannabinoid 
system has potential therapeutic advantages for cardiovascular therapy. One 
example is found with Anandamide that was shown to have protective effects during 
ischemia, where it reduced the infarct sizes (Underdown et al, 2005).The 
psychoactive component delta-9 tetrahydrocannabinol (THC) and its non-
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psychoactive isomer cannabidiol (CBD) have been found to protect the heart against 
ischemia/reperfusion injury (Shmist et al, 2006;Durst et al, 2007). 
 
Commercial synthetic cannabinoids have also been created to study the possible 
beneficial effect of the cannabinoids. One of these synthetic components is HU210, 
with which this project took a small scope view.HU 210 behaves very similar to THC 
in its pharmacological effects (Ottani et al, 2001).In an ischemia/reperfusion rodent 
model, HU-210 decreased the incidence of ventricular arrhythmias in rats through 
the activation of CB2 receptors (Krylatov et al, 2001). HU210 also reduced LDH 
leakage from isolated rat hearts during reperfusion, indicating reduced tissue 
necrosis, which was interestingly associated with reduced tissue cAMP during 
reperfusion (Maslov et al 2013). 
 
Given the fact that CB receptors are GPCRs and that they have been found to 
mediate their effects through cyclic nucleotides, it is imperative that the role of PDEs 
be investigated in cannabinoid-mediated cardio protection. In summary both 
endocannabinoids and phytocannabinoids have potential therapeutic applications in 
the cardiovascular setting especially in treatment of ischemia/reperfusion injury. 
Hypothesis and strategy 
 
We hypothesize that PDE4 plays a role in the development of ischemia/reperfusion 
damage and might therefore be considered for the clinical treatment of 
ischemia/reperfusion injury. This hypothesis is based on a number of observations; 
first and foremost, PDE activity has been shown to be necessary for protection of 
cardiomyocytes during anoxia (Geisbuhler et al 2001). These authors found that a 
general inhibition of PDEs with IBMX sensitized cardiomyocytes to ischemic 
damage, which was associated with enhanced ATP loss and an increased incidence 
of round injured cells (hypercontracture). PDEs function in a coordinated manner 
under the instruction of various stimuli, mostly known to be from GPCRs, in order to 
promote stimulus-specific cellular physiological effects. Thus any one or more of the 
known PDEs expressed in cardiomyocytes might be responsible for the sensitization 
of cardiomyocytes to ischemic damage, but PDE4 was considered in this thesis for 
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the following reasons. PDE4 exerts a dominant role in global cellular cAMP 
hydrolysis in rat cardiomyocytes (Johnson et al 2012). PDE4 is responsible for 
mediating b1- and b2-AR specific effects in normoxic cardiomyocytes (Mika et al 
2014, Gregg et al 2010), through cAMP compartmentation (Nikolaev et al 2006), 
which might also be true for ischemia/reperfusion, but has never been 
evaluated.PDE4 activity has been found to be necessary for insulin-mediated 
glucose uptake in isolated perfused rat hearts, which might also be true during 
ischemia and thereby play a role in cardio protection by insulin. Finally, cannabinoids 
such as THC and HU210 induce cardio protection during ischemia through CB 
receptors. These are GPCRs that regulate cyclic nucleotides, possibly through 
PDEs, of which PDE4 was considered here. 
 
AIM: 
 To find an alternative way to intervene during acute myocardial 
ischemia/infarction, through the g-protein coupled receptor (GPCR) pathways 
by evaluating the role of phosphodiesterase 4 (PDE 4) in mediating damage 
or protection during an ischemic event. 
OBJECTIVES: 
1. To test the hypercontracture effects of the cardiomyocytes with the inhibition 
of PDE4 by rolipram during ischemia with the combined administration of b-
AR agonists (dobutamine, folmoterol, isoproterenol), insulin and cannabinoids 
(THC and HU210). 
2. To test the fluorescence intensity of the cardiomyocytes, by looking at the 
mitochondrial membrane potential for apoptosis, with the inhibition of PDE4 
by rolipram during ischemia with the combined administration of b-AR 
agonists (dobutamine, folmoterol, isoproterenol), insulin and cannabinoids 
(THC and HU210). 
3. To test the cell viability of the cardiomyocytes with the inhibition of PDE4 by 
rolipram during ischemia with the combined administration of b-AR agonists 
(dobutamine, folmoterol, isoproterenol), insulin and cannabinoids (THC and 
HU210). 
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Chapter 2: Materials and Methods 
Rats 
For this study, male Wistar rats with a weight ranging from 250-300g were used. 
Animals were housed in the Animal Facility at the University of Stellenbosch, 
Tygerberg Campus. The animals were kept on a 12 hour day/night cycle at a 
constant temperature of 22˚С and 40% humidity. All animals had free access to food 
(standard rat chow) and fresh clean water. 
 
Ethical approval 
The use of animals for this study was approved by the Ethical Committee of the 
Faculty of Health Sciences, Stellenbosch University. Project number SU-ACUM13-
00018 was given to the study. This study conformed to the conditions described in 
the” Revised South African National Standard for the care and use of Animals for 
Scientific purposes” (South African Bureau of Standards, SANS 10386, 2008). 
 
Chemicals 
Rolipram, IBMX, isoproterenol, BRL-37344, HEPES, sodium pyruvate, sodium 
chloride (NaCl), 2, 3-butanedione monoxime (BDM),creatine, taurine, carnitine, 
M199 with Hank’s salts, blebbistatin, protease IV, 2−deoxy-glucose and JC-1 were 
obtained from Sigma Aldrich. Bovine serum albumin (BSA) fraction V, BSA fatty acid 
free (FAF) were obtained from Roche, collagenase Type II from Worthington, insulin 
from Eli Lilly, laminin/entactin (L/E) and penicillin/streptomycin (pen/strep) from BD 
Biosciences. Sodium pentobarbital, D-glucose, calcium chloride, potassium chloride 
(KCl), disodium hydrogen phosphate (Na2HPO4), sodium dihydrogen phosphate 
(NaH2PO4), and magnesium sulphate (MgSO4) were obtained from Merck. THC 
and Hu210 were obtained from Cayman Chemicals. Formoterol was produced by 
TOCRIS and donated by Dr Salie. 
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The adult rat ventricular myocyte model 
Coating of 96-well plates with laminin/entactin 
96-well costar black, clear bottom, tissue culture plates were coated with 
laminin/entactin (L/E). The plates were coated by adding 5μl of 1ug/ml L/E (diluted in 
PBS, 1mM CaCl2) in the centre of the well and thereafter the plates were incubated 
overnight at 5% CO2 and 37˚С. After overnight incubation, the excessive L/E was 
removed with suction and the plates were washed with 100μl/well of PBS containing 
1mM CaCl2, and allowed to dry in a laminar hood flow before plating the cells.  
 
Isolation of Adult Rat Ventricular Cardiomyocytes 
The cardiomyocyte isolation technique was based on a protocol published by Fischer 
et al, 1991 and reviewed by Louch et al, 2011. The rats were anesthetized by intra-
peritoneal injection of 0.3ml sodium pentobarbital (euthanaze). After checking the 
pinch response to ensure the rat is fully unconscious, it was sterilized in 70% ethanol 
and dissected inside a laminar flow hood. The chest was opened to expose the heart 
by using sterilized scissors. The hearts were excised with a large portion of the aorta 
intact and arrested in ice cold (4°C) Buffer A that contained 0.5mM CaCl2. Buffer A 
contained in mM: KCl 6; Na2HPO4 1; NaH2PO4 0.2; MgSO4 1.4; NaCl 128; HEPES 
10; D-glucose 11 and sodium pyruvate 2 (pH 7.4, 37°C, gassed with 95% O2 & 5% 
CO2). 
 
Thereafter, the aorta was clamped to the catheter (cannula). The hearts were 
mounted with a silk suture via the aorta onto the cannula of a Langendorff apparatus, 
and retrogradely perfused with calcium free buffer (buffer A) to wash out the 
excessive blood from the coronary arteries.  
 
After 5 minutes, the perfusion was switched to a digestion buffer (buffer B) 
containing 0.5% BSA fraction V, BSA (FAF), 440U/ml collagenase Type II, 0.2mg/ml 
protease IV and 18.0mM BDM added to buffer A. The first 10ml of the digestion 
buffer was discarded, while the rest was switched to recirculation and CaCl2 was 
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added to raise the Ca2+ concentration to 0.1mM. After 10 minutes another Ca2+-raise 
was done to increase the concentration to 0.2mM.The perfusion continued for 
another 10 -15 minutes until the heart was soft, swollen and soapy.  
 
To ensure sufficient digestion, the bubble trap’s air block was broken to test 
perfusion flow through digested heart with only gravitation. If the solution ran through 
easily, the heart was ready to be dissociated in buffer D. 
 
Thus after complete digestion of the heart, the ventricles were cut off and placed in a 
petri dish with buffer D {2/3 of buffer C [1×buffer A, 0.5% BSA (FFA), 0.5% BSA 
fraction V, 9.0mM BDM] and 1/3 of buffer B, 0.3mM CaCl2} . 
 
Ventricular cardiomyocytes were separated and dissociated by moving the tissue 
with a tweezer, back and forth in the buffer. The cell suspension was then filtered 
through a 200μm nylon filter into a 50ml conical tube. The cells were sedimented for 
10 minutes at room temperature and afterwards spun at 30× g for 2 minutes.  
 
The supernatant was removed as it contained most dead cells, other cells and 
debris. Only the pellet of viable cells was kept. The pellet was resuspended in buffer 
E1 (buffer C with 0.6mM CaCl2) and sedimented for 10 minutes, followed by E2 
(buffer C, 0.9mM CaCl2) and sedimented for 7 minutes and lastly resuspended in E3 
(buffer C, 1.2mM CaCl2) and sedimented for 5 minutes. Calcium was thus re-
introduced to the cells in this stepwise manner to a final concentration of 1.2mM. 
After sedimentation of 5 minutes, the supernatant was removed and the final pellet of 
calcium tolerant cells was resuspended in medium X culture buffer (MXCB) that 
contained 10μM blebbistatin (BBS) and 1.2mM CaCl2. The cardiomyocytes were 
assessed for viability after this step. MXCB is a buffer modified from M199 in order to 
provide better survival and was used to culture the ventricular 
cardiomyocytes.Bebbistatin is an inhibitor of myosin 2, and is used to reduce 
contraction during the plating process of the cardiomyocytes. 
 
Stellenbosch University  https://scholar.sun.ac.za
21 
 
 
Figure 2.1: Steps of heart digestion 
 
Assessment of viability 
Viability of cardiomyocytes was assessed by filling 2 chambers of the improved 
nubauer haemocytometer with the final cell suspension (MXCB). Thereafter, the 
numbers of rod- and round-shaped cardiomyocytes were counted separately using a 
light microscope, and their percentages determined. Rod-shaped cells were 
considered viable (live), whereas round cells were considered non-viable (dead). 
The cardiomyocytes were diluted in MXCB, containing 10μM BBS and 1.2mM 
CaCl2, and seeded at a density of 2500-5000 rod shaped cells per well in 96-well 
culture plates, followed by overnight culture of the cells at 5%CO2 and 37˚С in the 
incubator. The experimental procedure with the different treatment groups during 
ischemia continued the following day and will be discussed in the experiments 
section. 
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Experimental procedures 
The experimental procedure/timeline can be seen in figure 2.2A to figure 2.2C. 
 
In figure 2.2A it indicates the experimental time line when no drugs are administered. 
This is the experimental procedure for the normal ischemic treatments without any 
treatments.  
The normoxic treatment group also follows this experimental timeline. The only 
difference is instead of administering the ischemic wash buffer during the 20 minutes 
indicated; it is replaced with the normal CMCB wash buffer, without SDT and 2DG, 
and also without any drug treatments. 
 
In figure 2.2B it indicates the administration of drugs prior to ischemia and 
throughout the 20 minutes simulated ischemia. There are treatments which were 
administered during ischemia and reperfusion. So for this, the administration time of 
drugs would shift from during ischemia and onwards till end of the reperfusion stage. 
 
In figure 2.2C it indicates when the drugs are only administered during ischemia. It is 
thus the same timeline as in figure 2.2A but the only difference is the drug treatments 
which were administered during the 20 minutes of simulated ischemia.  
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The overnight cultured cardiomyocytes in 96 well plates were subjected to simulated 
ischemia/reperfusion, with different treatment conditions added to the ischemic 
buffer. Do note that the 96 well plates were used in order to set up a high throughput 
system and compare more conditions per experiment. As can be seen in the figure 
2.2 above, the cardiomyocytes received a growth medium by adding 100μl per well 
of the freshly prepared wash buffer (modified MXCB - BBS) on top of the overnight 
MXCB (+BBS). After overlaying the culture plates, they were incubated for 15 
minutes @ 37˚С.  
 
After the 15 minutes of incubation, the media in the wells was discarded and another 
100μl/well of fresh MMXCB (-BBS) was added to the wells and incubated for 
10minutes at 37˚C. This was again repeated and incubated for another 10minutes 
(total feeding time= 35 minutes) 
 
Control cells were incubated in MMXCB, while ischemia was simulated by incubating 
cardiomyocytes for 20minutes at 37˚С with ischemic wash buffer [with 10mM sodium 
hydrosulphite (SDT) and 3mM 2−deoxyglucose (2−DG), (−HEPES), pH 6.4]. After 20 
minutes, the cardiomyocytes were washed twice with 200μl MMXCB and reperfused 
with 100μl MMXCB for 15 minutes at 37˚С. The time and concentrations used to 
elicit ischemia (mimic ischemia) was determined by another colleague 
(Labuschagne, SW, 2015).  
During the ischemic event, the different drugs were administered during ischemia in 
separate wells. The conditions had Ischemic buffer with 10uM rolipram, 10uM 
Dobutamine, 10uM and 10nM HU210, or combination of the Dobutamine with 
rolipram or HU210 and rolipram, given only during the ischemic period. 
Thereafter, the cells were stained with 3.8mM JC-1 for 10 minutes at 37˚С and 
washed twice with 100μl of MMXCB. A stabilization period of 30 minutes was given 
after staining and followed by fluorescence microscopy [excitation: 490nm; emission: 
590nm and 530 for JC-1 aggregates (red) and monomers (green) respectively]. 
Images were captured, analysed, and data expressed as red/green fluorescence 
ratio as a live index. Increased red fluorescence indicated increased viability. And 
decreased red fluorescence indicated increased cell death. The cell length and the 
total number of cells were measured as well.  
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The dissipation of the mitochondrial electrochemical membrane potential gradient is 
known as an early event in apoptosis. In normal cells, due to the membrane potential 
gradient, the dye concentrates in the mitochondrial matrix, where it forms red 
fluorescent aggregates.  
Any event that dissipates the mitochondrial membrane potential (like an ischemic 
event) prevents the accumulation of the JC-1 dye in the mitochondria and thus, the 
dye is dispersed throughout the entire cell leading to a shift from red to green 
fluorescence (JC-1 monomers).   
 
Microphotograph Analysis 
By using a fluorescence microscope the captured images of cells were taken. The 
captured images represents one field view per well at 10× objectives. The analysis 
was done by measuring the captured images of cells. The cell count, cell length and 
fluorescence analyses were determined directly from the microphotographs.  
 
 For the cell count the total numbers of ARCMs (rod and round) were counted. The 
rod shaped and round shaped cells (hyper-contracted cells) were counted in each 
well for all the different conditions within 3 to 8 hearts and compared.  
 
For the cell length, the length in each cell was measured using the Image J, FIJI 
software program. The average length of all the cells per well (per condition) was 
determined and compared within the different amount of hearts. 
 
For fluorescence analysis, red (R) and green (G) fluorescence in each cell were 
measured using the Image J, FIJI software program. The ratio of Red and green 
fluorescence was calculated for each cell, and the averages per well was determined 
in each condition and within the different amount of hearts. 
 
All of the photos are taken after reperfusion and JC-1 staining and thus all 
parameters: cell viability, R/G ratio and cell length are assessed after reperfusion. 
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Figure 2.3: Cell analyses through Image J Fiji 
 
cAMP ASSAY 
Adult rat cardiomyocytes cultured overnight at 2500 cells/well in duplicate for 2 rats, 
were assessed during normoxia for cAMP responses to the following drugs: 10uM 
rolipram, 100nM isoproterenol, 100uM IBMX, 10nM rolipram with 100nM 
isoproterenol, 100uM IBMX with 100nM isoproterenol. The cardiomyocytes were 
stimulated with these drugs for 10 minutes at 37C. Thereafter the stimulation buffer 
was removed and the cell permeabilized with 80ul/well of somatic cell releasing 
reagent (FL-SAR) from SIGMA. After 5 min incubation at room temperature, the 
somatic cell releasing reagent was harvested from the cells and duplicate treatments 
merged per treatment per heart. 50ul of each sample was assayed for cAMP 
according to the manufacturer’s protocol, using the cAMP enzyme immunoassay kit 
(CA201) from SIGMA. 
 
Statistical Analysis 
All values are expressed as the mean ± standard error of the mean (SEM). Graph 
Pad Prism (version 6.0) was used to compare results, using one-way analysis of 
variance (ANOVA) and Bonferonni was used as the post hoc test. Probability values 
of less than 0.05 (p< 0.05) were considered significantly different.  
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Chapter 3: Results 
The drugs used during these experiments included dobutamine and isoproterenol 
which was expected to exacerbate damage with B1 stimulation during ischemia, 
insulin administered as a protective treatment during ischemia.  
Formoterol, a b2AR-agonsit, BRL-37344 as a b3AR-agonist and THC (main 
component of marijuana and a phytocannabiniod) as well as HU210 a synthetic 
cannabinoid (also influencing the CB-receptors) was used to elicit protection with 
b2AR, b3AR and cannabinoid receptor stimulation during ischemia.  
The 3-isobutyl-1-methylxanthine (IBMX) is a non-specific phosphodiesterase inhibitor 
3-isobutyl-1-methylxanthine used in the total cAMP measurement experiment.  
Rolipram is the drug used to inhibit PDE4 and was combined with the different drug 
treatments to evaluate if this would elicit protective effects or worsen the pathology 
caused by the ischemic event. 
         
Figure 3.1 photo of the normoxia cells from experiment.    Figure 3.2: photo of the ischemia cells from experiment 
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Effect of insulin and PDE4 inhibition on ischemia/reperfusion injury 
Figure 3.3A shows the average cell lengths of cardiomyocytes at the end of 
ischemia/reperfusion, when treated during ischemia with 0.3mIU insulin and rolipram 
(1, 10 and 50uM) alone and in combination. A significant difference (p ≤ 0.01) was 
found between the ischemic untreated (71.4±2.0um)and the normoxic untreated 
(115.9±1.2um) cells. This indicates a significant development of hypercontracture 
induced in the cardiomyocytes by simulated ischemia/reperfusion. Hypercontracture 
was not altered by any of the treatments, given that the results didn’t show any 
improvement in cell length with any of the treatments applied during ischemia (range: 
63.9±2.2um - 75.3±9.0um). 
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Figure 3.3A: Graph of cell lengths in micrometre (um) as an indication of hypercontracture after 
ischemia/reperfusion. Comparing different concentrations of rolipram administered during ischemia 
and normoxic conditions, with and without insulin. N=3, with **= p ≤ 0.01compared to normoxia 
untreated. 
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Figure 3.3B: Graph of red over green (R/G) fluorescence intensity ratio evaluating cell viability through 
mitochondrial membrane potential. Comparing different concentrations of rolipram administered 
during ischemia and normoxic conditions, with and without insulin. N=3 (*=p≤ 0.05 and **= p ≤ 0.01 
compared to ischemia untreated. (##=p ≤ 0.01 compared to normoxia untreated). 
 
In figure 3.3B the red / green (R/G) fluorescence ratio was plotted and no significant 
difference was observed between the untreated normoxic group and untreated 
ischemia group. Insulin administration during normoxia with no rolipram (1.55± 0.11) 
significantly (p ≤ 0.01) reduced the ratio of R/G compared to the normoxic untreated 
group. Compared to untreated ischemia (1.99 ± 0.12), rolipram treatment alone 
reduced R/G at concentrations of 1uM (0.98 ± 0.33, p ≤0.05), 10uM (0.92 ± 0.35, p 
≤0.05) and 50uM (0.57 ± 0.20, p ≤0.01). Similar results were also found when 3mIU 
insulin was combined with rolipram at 1uM, 10uM and 100uM. 
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Figure 3.3C: Graph of the percentage viable cells, comparing the effect of different concentrations of 
rolipram administered during ischemia and normoxic conditions respectively, with and without insulin. 
N=3. (**= p ≤ 0.01 compared to ischemia untreated; ****=.p ≤ 0.0001 compared to ischemia untreated 
and ####=.p ≤ 0.0001 compared to normoxic untreated). 
 
As shown in figure 3.3C, the percentage viable cells was significantly reduced 
(p≤0.0001) by the ischemic untreated condition (20.3±4.1%) compared to the 
normoxic untreated condition (94.6±1.7%). This indicates that a proper ischemic 
insult was achieved to study the effects of the different drugs. When rolipram 
concentrations in ischemia were compared to untreated ischemia, a significant 
decrease in viability was found with the concentrations of 1uM (4.52 ± 0.96%, 
p≤0.0001) and 10uM (8.20 ± 2.15%, p≤0.01) rolipram. Similar results were found 
when rolipram was administered with insulin during ischemia. Considering these 
findings the 10uM concentration was chosen to use throughout the project as this is 
the concentration also used in most literature (Bethke, T. et al, 1992; Georget, M. et 
al, 2003; De Arcangelis, V. et al, 2008; Qvigstad, E. et al, 2010; Beca, S. et al, 2011; 
Leroy, J. et al 2011; Parks, R.J. et al, 2014). The insulin treatment with 3IU/ml did 
not show a protective effect, which is in contrast to the literature. No differences were 
found between the normoxic conditions when compared to the normoxic untreated. 
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Effect of B1 receptor stimulation on ischemia/ reperfusion injury 
In figure 3.4A the average cell lengths obtained after ischemia/reperfusion, in the 
presence and absence of dobutamine were compared. A significant difference (p ≤ 
0.05) was found with the ischemic untreated 0uM Dobutamine (60.8±1.8um) 
compared to normoxic untreated 0uM Dobutamine (112.3±0.8um). This indicates 
that the ischaemic conditions were enough to result in a proper insult which resulted 
in a decrease in cell length, which indicates hyper contracture. The results did not 
show a significant improvement or further damaging effect during ischemia with the 
different dobutamine concentrations. The mean length range for the different 
treatments during ischemia was between 59.0±1.5um and 64.3±3.7um. 
0
u
M
1
u
M
1
0
u
M
1
0
0
u
M
0
u
M
1
u
M
1
0
u
M
1
0
0
u
M
1
u
M
1
0
u
M
1
0
0
u
M
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
C
e
ll
 l
e
n
g
th
 i
n
 u
m
N o rm o x ic
Is c h e m ia  a n d
R e p e r fu s io n O n ly  R e p e r fu s io n
Is c h e m ia
*
D o b u ta m in e
 
Figure 3.4A: Graph of cell lengths in micrometre (um) as an indicator of contracture. Comparing 
different concentrations of dobutamine administered during ischemia/reperfusion, reperfusion only 
and during normoxic conditions. N=4. (*= p ≤ 0.05 compared to normoxia untreated). 
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Figure 3.4B: Graph of red over green (R/G) ratio of fluorescence intensity ratio as an indicator of 
mitochondria function and cell viability. Comparing different concentrations of dobutamine during 
ischemia/reperfusion, reperfusion only and during normoxic conditions. N=4. (*= p ≤ 0.05 compared to 
normoxia untreated). 
 
In figure 3.4B, no significant differences were found with R/G ratio when the 
normoxic untreated (1.3±0.1) was compared to the ischemia untreated (0.7±0.2). A 
significant difference (p≤ 0.05) was however found between the normoxic untreated 
0uM Dobutamine when compared with the Dobutamine 10uM administered during 
ischemia and reperfusion (0.6±0.1). 
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Figure 3.4C: Graph of total viable cells in percentage, comparing different concentrations of 
dobutamine during ischemia/reperfusion, reperfusion only and during normoxic conditions. N=4. (*= p 
≤ 0.05 compared to normoxia untreated). 
 
In figure 3.4C a significant difference of p ≤ of 0.05 and smaller was found when 
comparing the percentage cell viability of ischemic conditions to normoxic untreated 
0uM Dobutamine. The mean percentage viability of the normoxic untreated 0uM 
Dobutamine group was 92.2±1.1% and the ischemic untreated 0uM Dobutamine 
group was 13.5±2.8%. None of the treatments in the ischemic conditions or during 
reperfusion altered cell viability (7.4±4.2% to 17.2±7.6%). There were also no 
significant differences between the normoxic untreated 0uM compared to the other 
normoxic treatment concentrations of Dobutamine. 
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Effects of Isoproterenol on ischemia/reperfusion injury 
Figure 3.5A shows cell lengths compared for different concentrations of isoproterenol 
administered during normoxic conditions only, during ischemia and reperfusion, and 
lastly administered only during reperfusion. A significant difference (p ≤ 0.05) was 
found when the different ischemia conditions were compared to the normoxic 
untreated (0uM Isoproterenol). The latter had a mean cell length of 109.9±1.7um and 
the ischemia untreated showed a mean cell length of 68.7±3.2um. Cell lengths for 
isoproterenol treatments during ischemia/reperfusion and reperfusion ranged from 
62.7±2.8um to 67.2±4.2um, Isoproterenol had no effects on cell length when 
administered to cardiomyocytes under normoxic conditions. 
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Figure 3.5A: Graph of cell lengths in micrometre (um), comparing different concentrations of 
isoproterenol administered during ischemia/reperfusion, reperfusion only and only during normoxic 
conditions. N=4. (*= p ≤ 0.05 compared to normoxic untreated 0uM). 
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Figure 3.5B: Graph of red over green (R/G) fluorescence intensity ratio as a measure of mitochondrial 
function and cell viability. Comparing different concentrations of isoproterenol during 
ischemia/reperfusion, reperfusion only and during normoxic conditions. N=4 
 
In Figure 3.5B, the R/G fluorescence ratio was studied to assess the cell viability 
after ischemia/reperfusion. Comparison between the different concentrations of 
isoproterenol during ischemia/reperfusion, reperfusion and also during normoxic 
conditions showed no differences. The normoxic untreated group had a mean 
fluorescence intensity of 2.2±0.2 and the ischemia untreated 0uM Isoproterenol had 
a mean fluorescence intensity of 1.3±0.2. The normoxic treatments had no 
significant differences when compared to the normoxic untreated group. 
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Figure 3.5C: Graph of total viable cells in percentage Comparing different concentrations of 
isoproterenol during ischemia/reperfusion, reperfusion only and during normoxic conditions. N=4 and 
p. (*= p ≤ 0.05 compared to normoxia untreated). 
 
Figure 3.5C shows the percentage viable cells compared between the different 
concentrations of isoproterenol during ischemia/reperfusion, reperfusion only and 
during normoxic conditions. All the ischemia treatments showed a significant 
difference (p ≤ 0.05) compared to normoxic untreated (84.1±5.7%) The ischemia 
untreated 0uM had a viability of 16.9±5.8%, indicating that cell viability reduced by 
67.2% after ischemia/reperfusion. No significant differences were observed when the 
different treatments were administered during ischemia/reperfusion and reperfusion 
only, compared to the ischemia untreated 0uM group. 
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Effects of seven different treatments in ischemia with and without the 
combined administration of 10uM rolipram. 
In Figure 3.6A the cell lengths were plotted to evaluate cardiomyocyte 
hypercontracture after ischemia/reperfusion. A comparison between the different 
treatments (100nM isoproterenol, 10uM formoterol, 10uM dobutamine, 10nM 
HU210) applied during ischemia, with and without 10uM Rolipram was done. A 
significant difference (p≤0.0001) was observed between the ischemia untreated 
(58.2±3.3um) compared to the normoxic untreated group (104.7±6.7um). A similar 
degree of hypercontracture was found for all the other treatments given during 
ischemia, which indicates a significant ischemic insult was induced. HU210 was also 
tested in this experiment, comparing administration during ischemia only, and during 
ischemia/reperfusion with untreated ischemia, and no protection was found. The 
mean cell length range for the treatments during ischemia was between 57.6±1.7um 
and 69.1±4.7um.  
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Figure 3.6A Graph of cell lengths in micrometre (um), evaluating cardiomyocyte hypercontracture. 
Comparing different treatments: 100nM isoproterenol (Iso), 10uM formoterol (For), 10uM dobutamine 
(Dob), and 10nM HU210 during ischemia, with and without 10uM Rolipram. N=4 
(****=p≤0.0001compared to untreated normoxic control). 
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Figure 3.6B Graph of red over green (R/G) fluorescence intensity as an indicator of mitochondrial 
viability. Comparing different treatments: 100nM isoproterenol (Iso), 10uM formoterol (For), 10uM 
dobutamine (Dob), and 10nM HU210 during ischemia, with and without 10uM Rolipram. N=4 
(*=p≤0.05 compared to ischemia untreated, **=p≤0.01 compared to ischemia untreated and ## = 
p≤0.05 compared to normoxia untreated).  
 
The graph of R/G fluorescence ratio (figure3.6B) shows a significantly (p ≤ 0.05) 
higher mitochondrial viability for ischemia administered HU210 (1.5±0.0) compared 
to ischemia untreated (1.0±0.1). A difference (p ≤ 0.01) was observed between the 
normoxic untreated (1.6±0.0) and ischemia untreated (1.0±0.1), indicating a 
significant insult due to ischemic/reperfusion. The isoproterenol treatment during 
ischemia (1.0±0.1) and rolipram treatment during ischemia (0.9±0.1) were similar to 
ischemia untreated, but when combined during ischemia, isoproterenol and rolipram 
combined treatment significantly (p ≤ 0.01) improved fluorescence intensity 
(1.6±0.1). 
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Figure 3.6C Graph of total viable cells over total viable and non-viable cells in percentage. Comparing 
different treatments: 100nM isoproterenol (Iso), 10uM formoterol (For), 10uM dobutamine (Dob), and 
10nM HU210 during ischemia, with and without 10uM Rolipram. N=4 (****=p≤0.0001 compared to 
control). 
 
Figure 3.6C shows that ischemia untreated had a mean percentage viability of 
10.5±2.8% and the normoxic untreated had a mean percentage of 91.3±0.8%. This 
indicates a significant (p ≤ 0.0001) loss of viable cells during the 
ischemia/reperfusion insult. No other differences were observed with any of the 
treatments applied during ischemia or for HU210 during ischemia/reperfusion. 
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Figure 3.6D: cAMP measurement. Cultured adult cardiomyocytes were incubated for 10 minutes with 10uM 
rolipram (Rol), 100nM Isoproterenol (Iso), 100nM isoproterenol with 10uM rolipram, 100uM IBMX, and 100nM 
isoproterenol + 100uM IBMX, followed by total cAMP measurement. n=2 
 
The data in this graph (figure3.6D) shows that cAMP production at the basal level is 
very low in the untreated cardiomyocytes (0.33 ± 0.02pmol/ml), and remained so 
even in the presence of PDE4 inhibition with rolipram (0.56 ± 0.05pmol/ml), while 
showing a slight increase by total PDE inhibition with IBMX (1.626 ± 0.3225). 
Unfortunately no statistical analysis could be done because only an n-value of 2 was 
used in this experiment. The production of cAMP by 100nM Isoproterenol (0.38 ± 
0.02) was not visible in the absence of PDE inhibition, but increased 16 fold when 
combined with PDE4 inhibition (Iso + Rol: 6.38 ± 0.61pmol/ml) and 35 fold with total 
PDEs inhibition (Iso + IBMX: 13.54 ± 7.446pmol/ml).  
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Effects of 10uM rolipram administered at different time points prior to 
ischemia. 
Figure 3.7A shows a comparison of cell length between 10uM formoterol and 10uM 
dobutamine treatment during ischemia respectively, with and without 10uM rolipram, 
where rolipram was added from 5minutes prior to ischemia. A significant difference 
with a p≤0.0001 was observed between the ischemia untreated (76.0±1.9um) 
compared to the normoxic untreated group(114.2±3.0um). This indicates a proper 
ischemic insult. No significant differences were observed in the other ischemia 
treated groups compared to ischemia untreated. 
.
u
n
tr
e
a
te
d
u
n
tr
e
a
te
d
F
o
r
 1
0
u
M
D
o
b
 1
0
u
M
u
n
tr
e
a
te
d
F
o
r
 1
0
u
M
D
o
b
 1
0
u
M
F
o
r
 1
0
u
M
D
o
b
 1
0
u
M
u
n
tr
e
a
te
d
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
C
e
ll
 l
e
n
g
th
 i
n
 u
m
N o rm o x ic tre a tm e n ts  d u r in g  Is c h e m ia
R o lip ra m  1 0 u M
d u r in g
R o lip ra m  1 0 u M
5  m in  p r io r  a n d
d u r in g
R o lip ra m  1 0 u M
1 0  m in  p r io r  a n d
d u r in g
****
 
Figure 3.7A. Graph of cell lengths in micrometre (um), evaluating cardiomyocyte hypercontracture. 
Comparing 10uM of dobutamine (Dob) and formoterol (For) during ischemia, with and without 
different administrations treatment of 10uM rolipram. N=4. (****=p≤0.0001 compared to normoxic 
untreated).  
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Figure 3.7B. Graph of red over green (R/G) fluorescence intensity ratio. Comparing 10uM of 
dobutamine (Dob) and 10uM formoterol (For) during ischemia conditions with and without different 
administration treatments of 10uM rolipram. N=4.  
 
In Figure 3.7B, the R/G fluorescence ratio was studied to evaluate cell viability after 
ischemia/reperfusion. 10uM formoterol and 10uM dobutamine administered during 
ischemia with different administered time points of rolipram 10uM, did not show a 
significant difference. No differences were found between the normoxic untreated 
group (0.9±0.05) and the ischemia untreated (0.9±0.1), or any of the treatment 
groups (0.9±0.0 and 1.0±0.1) 
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Figure 3.7C. Graph of cell viability in percentage. Comparing 10uM of dobutamine (Dob) and 10uM 
formoterol (For) during ischemia conditions with and without different administration treatments of 
10uM rolipram. N=4 (****=p≤0.0001 compared to control).  
 
In figure 3.7C shows that the mean percentage viability for the ischemia untreated 
group (33.7±2.7%) was significantly (p ≤ 0.0001) reduced compared to the normoxic 
untreated group (83.6±6.8%). None of the treatments during ischemia altered 
percentage cell viability (34.3±6.6% to 46.1±9.5%) when compared to the ischemia 
untreated group. 
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Cannabinoids and b-AR agonists in combination with and without 10uM 
rolipram administered 5minutes prior to and during ischemia. 
In Figure 3.8A cell lengths in um show cardiomyocyte hypercontracture compared 
between the different treatments during ischemia, with and without 10uM Rolipram 
administered from 5min pre-treatment and pertreatment ischemia. A significant 
difference (p ≤ 0.0001) was observed between the ischemia untreated group 
(70.8±4.2um) and the normoxic untreated group (95.6±0.6um). 100nM isoproterenol 
without 10uM rolipram during ischemia had a mean cell length of 59.7±2.7um, which 
was significantly shorter than that of the ischemia untreated group. 10uM BRL-37344 
treatment without 10uM rolipram during ischemia (57.4±0.2um) had a significantly (p 
≤ 0.01) shorter cell length compared to ischemia untreated. This was also true for 
HU210 administration when rolipram was administered from 5 min before and during 
ischemia (57.3±2.3um, p ≤ 0.01) compared to the ischemia untreated group.  
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Figure 3.8A Graph of cell lengths in micrometre (um), evaluating cell hypercontracture. Comparing different 
treatments (100nM isoproterenol (Iso), 10nM HU210, 10uM THC, and 10uM BRL-37344) during ischemia, with 
and without 10uM Rolipram administered from 5 min prior and during ischemia. N=4 (*=p≤0.05 compared to 
ischemia untreated, **=p≤0.01 compared to ischemia untreated and ####=p≤0.0001compared to normoxic 
untreated).  
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Figure 3.8B Graph of red over green (R/G) fluorescence intensity ratio. Comparing different 
treatments (100nM isoproterenol (Iso), 10nM HU210, 10uM THC, and 10uM BRL-37344) during 
ischemia, with and without 10uM Rolipram administered from 5 min prior and during ischemia. N=4 
(**=p≤0.01 compared to ischemia untreated).  
 
In Figure 3.8B the R/G fluorescence intensity was measured for the different 
treatments (100nM isoproterenol, 10nM HU210, 10uM THC, and 10uM BRL-37344) 
during ischemia, with and without 10uM Rolipram administered 5 minutes prior and 
throughout ischemia. R/G fluorescence ratio did not show a significant decrease 
when the ischemia untreated group (1.2±0.1) was compared to the normoxic 
untreated group with a fluorescence intensity of 1.5±0.1. A significant difference (p ≤ 
0.01) was however found between when 10uM THC treatment during ischemia 
without rolipram (0.3±0.1) was compared to the ischemia untreated group (1.2±0.1).  
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Figure 3.8C Graph of cell viability in percentage. Comparing different treatments (100nM 
isoproterenol (Iso), 10nM HU210, 10uM THC, and 10uM BRL-37344) during ischemia, with and 
without 10uM Rolipram administered from 5 min prior and during ischemia. N=4 (**=p≤0.0001 
compared to ischemia untreated). 
 
In Figure 3.8C cell viability in percentage (total rod over total cells) show 
cardiomyocyte viable cell attachment compared between the different treatments 
during ischemia, with and without 10uM Rolipram administered from 5min pre-
treatment and pertreatment ischemia. A significant difference (p ≤ 0.0001) was 
observed between the ischemia untreated group (31.9±1.3%) and the normoxic 
untreated group (79.8±4.5%). No further differences were observed in the other 
groups compared to ischemia, which might also be due to a very potent ischemic 
treatment. 
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Effects of cannabinoids and b-AR agonists with rolipram during 
ischemia only. 
In figure 3.9A, the average cell lengths were compared to one another in 10uM 
Dobutamine (Dob), 10uM formoterol (For), 100nM isoproterenol (Iso), 10uM BRL-
37344, 10uM THC, and 10nM HU210. A significant difference with a p-value ≤ 
0.0001 was found between the ischemic untreated condition (58.8±1.6um) when 
compared to normoxic untreated condition (95.9±2.3). This indicates a proper insult 
with the ischemic conditions applied. There are seven different treatment conditions 
during ischemia that all received a combination of rolipram 10uM administration 
during ischemia and also without the rolipram administration. The results did not 
show a significant improvement or further damaging effect during ischemia with the 
other different treatments when compared to ischemia untreated, except for the THC 
10uM without the rolipram 10uM administration. The significant difference between 
these two groups had a p-value≤0.05 with mean cell lengths of Ischemia untreated 
58.8±1.6um and THC 10uM without rolipram 10uM, 65.7±2. 
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Figure 3.9A Graph of cell lengths in um, resembling cell contracture. Comparing different treatments (10uM 
Dobutamine (Dob), 10uM formoterol (For), 100nM isoproterenol (Iso), 10uM BRL-37344, 10uM THC, and 10nM 
HU210) during ischemia, with and without 10uM Rolipram administered during ischemia. N=7 (*=p≤0.05 
compared to ischemia untreated and ****=p≤0.0001compared to normoxic untreated).  
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Figure 3.9B Graph of red over green fluorescence intensity. Comparing different treatments (10uM Dobutamine 
(Dob), 10uM formoterol (For), 100nM isoproterenol (Iso), 10uM BRL-37344, 10uM THC, and 10nM HU210) 
during ischemia, with and without 10uM Rolipram administered during ischemia. N=7 (*=p≤0.05 compared to 
normoxic untreated). 
 
In figure 3.9B, the R/G fluorescence intensity was measured and the different 
treatments during ischemia with and without rolipram 10uM administration were 
compared. A significant difference was found between the ischemic untreated group 
(1.3±0.2) compared to the normoxic untreated group (2.1±0.2) with a p-value≤0.05. 
The HU210 that received the rolipram combination during ischemia with a mean 
fluorescence of 0.9±0.2 had a lowering effect on fluorescence intensity when 
compared to the normoxic untreated group (2.1±0.2). The formoterol given during 
ischemia without rolipram (1.2±0.3) also showed a significant difference when 
compared to the untreated normoxic conditions with a p-value≤ 0.05. The same 
significant difference was found for B3 (1.1±0.2) and untreated (1.2±0.2) treatments 
in combination with rolipram when compared to normoxic untreated groups 
(2.1±0.2). The range for the ischemic conditions varied between 0.9±0.2 and 
1.6±0.4. 
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Figure 3.9C Graph of cell viability in percentage. Comparing different treatments (10uM Dobutamine (Dob), 10uM 
formoterol (For), 100nM isoproterenol (Iso), 10uM BRL-37344, 10uM THC, and 10nM HU210) during ischemia, 
with and without 10uM Rolipram administered during ischemia. N=7 (*=p≤0.05 compared to normoxic untreated).  
 
Figure 3.9C shows the percentage viability of the total viable cells over total viable 
and non-viable cells. It compares the different treatments during ischemia with and 
without rolipram 10uM administration. The only significant difference through a one-
way ANOVA variance test had a p-value≤0.05 and was found between the normoxic 
untreated (79.3±3.0%) and all the ischemic groups (ischemia untreated 16.0±5.1%). 
This shows the sufficient knockdown of our ischemia, but unfortunately no significant 
differences were found between the different ischemia conditions when compared to 
ischemia untreated. The mean percentage range for the different ischemia 
conditions varied between 10.4±2.1% and 23.0±2.9. 
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Chapter 4: Discussion 
Isolation procedure of the cardiomyocytes 
Most work on PDE expression in the cardiovascular setting made use of whole heart 
or tissue, this allowed for the possibility that some PDE activity came from vascular 
cells or fibroblasts, instead of only cardiomyocytes (Maurice et al, 2003; Johnson et 
al, 2012). Using cultured isolated adult cardiomyocytes allows the evaluation of 
PDEs in a pure cell population, and was therefore used in this study. 
 
Drug treatments in normoxic conditions 
The drug treatments administered during ischemia were also tested in normoxic 
conditions to determine whether the drug had any influence on the cardiomyocytes in 
the absence of ischemia. No differences were found between the normoxic drug 
treatments when compared to the normoxic untreated group. Due to the absence of 
drug effects during normoxia, normoxic drug controls were omitted from later 
experiments in order to maximize on the number of ischemic test groups per 
experiment. In addition, some of the experimental treatments (formoterol, THC, 
HU210 and BRL-37344) administered during ischemia without the indication of 
normoxic treatments, were tested by other colleagues and they found no significant 
differences with untreated normoxia (A Botha, SW Labuschagne and E Samodien). 
DMSO and ethanol vehicle controls were also tested by colleagues and were found 
to have no effects during normoxia or ischemia/reperfusion (data not shown). 
 
Ischemic insult compared to viable control cells 
Normoxia and ischemia/reperfusion treated cardiomyocytes were subjected to the 
same number of washes, in order to normalize for loss of cells through cell washes.  
The cell washing did not affect the percentage cell viability which ranged between 
79.3±2.97% and 94.6±1.7% for the normoxic untreated through all the different 
experiments during the study. When the cardiomyocytes were treated with ischemia 
buffer, the percentage viability decreased to a range of 10.5±2.8% to 33.7±2.7%. 
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This shows a proper ischemic insult, as the percentage viability decreased, while the 
non-viable round shaped cells increased as can be seen in figure 3.1 and figure 3.2. 
The cell lengths also showed a proper insult from ischemia, where cell lengths of 
normoxic untreated groups (95.59±0.6382um to 115.93±1.174 um) were significantly 
reduced to 58.20±3.330um to 75.95±1.866um by ischemia. The reduction in cell 
length resembles hypercontracture of the rod shaped cells to round shaped cells. 
 
Non-protective effect of Insulin treatment during ischemia 
The results also highlighted that the Insulin treatment did not show any protection 
(figure 3.3A, B and C) as predicted, in contrast with literature (Abdallah et al, 2006; 
Jonassen et al, 2001; Zhang et al, 2005). A possible explanation for the absence of 
protection with insulin in this study might be due to the low n-value, given that only 3 
male wistar rats were used. With later experiments, another lab colleague did 
however find cardiac protective effects form insulin as described in literature 
(Labuschagne SW, 2015). It is also possible that the ischemic conditions used, 3mM 
2DG and 10mM SDT, were too harsh, given that most of the ischemic untreated 
groups had a percentage viability of less than 20%. A severe ischemic insult could 
possibly have blocked of the insulin’s tyrosine receptors due to a very low pH. The 
insulin protection should therefore be tested again for a shorter period of ischemic 
time with the same chemical ischemia, or under a longer ischemic time with a lower 
dose of chemical ischemia. Insulin experiments were discontinued and not tested in 
combination with PDE4 inhibition. No answer came from this thesis with regards to 
the involvement of PDE4 in insulin-mediated cardio protection, and therefore it 
should be re-investigated in the future with a greater n-value and milder ischemic 
conditions or under hypoxic conditions. 
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Absence of protection with b2AR, b3AR and cannabinoid receptor 
stimulation during ischemia 
The 10uM concentration formoterol used in this project was decided based on a 
dose response of formoterol (10nM, 10uM and 100uM) treatment during ischemia, 
on survival parameters at the end of ischemia/reperfusion done by Labuschagne, 
SW, 2015 with the same ischemic regime as in this project. Both 10uM and 100uM 
formoterol was found to reduce hypercontracture and increase cell viability, but 
10uM was chosen for this study because it was closer to concentrations (1nM-1uM) 
used in the literature (Salie et al 2011, Somvanshi et al 2014). However, no cardio 
protection was found with 10uM formoterol in this study, with no change in 
hypercontracture or cell viability compared to untreated ischemia/reperfusion (figures 
3.6, 3.7 and 3.9). Under the harsh ischemic conditions used in this thesis, which 
reduced percentage cell survival to10.5±2.8 % (in figure 3.6C), 33.7±2.7% 
(figure3.7C) and 16.0±5.1% in the ‘Effects of cannabinoids and b-AR agonists with 
rolipram during ischemia only’ experiment (figure 3.9C). Maybe if 100uM formoterol 
was chosen, it would have exerted a cardio protective effect. 
 
The 10uM concentration of BRL-37344 (b3AR agonist) chosen for this study is 
based on literature where 7uM BRL-37344 protected cardiomyocytes from injury in a 
model of hypoxia/reperfusion (García-Prieto et al 2014). BRL-37344 treatment 
without 10uM rolipram during ischemia (57.4±0.2um) had a significantly (p ≤ 0.01) 
shorter cell length compared to ischemia untreated (70.8±4.2um) in figure 3.8A. No 
further changes in cardiomyocyte survival parameters were seen with 10uM BRL-
37344 in the last experiment (figure 3.9) with BRL-37344, which was also in 
contrasts with the literature that implicates stimulation of this receptor with cardio 
protection (Aragón et al 2011,García-Prieto et al 2014). The absence of protection 
with yet another cardio protective agent strongly suggest a common problem, which 
yet again might be a function of the huge loss in viable cells, given that the range of 
viable cells at the end of ischemia/reperfusion was between 10.4±2.1% and 23.0±2.9 
in figure 3.9C. 
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The 10uM concentration THC used in this project was decided based on a dose 
response of THC treatment during ischemia, on survival parameters at the end of 
ischemia/reperfusion done by another lab colleague (Dr. Samodien, E) also with the 
same ischemic regime as this project. it was found to increase cell viability and 
decrease cell contracture. However in this study, 10uM THC did not show a 
protection or an increase in cell length in the experiment done, as can be seen in 
figure 3.8A. It did however correlate with Dr E Samodien’s findings when it 
decreased the total R/G fluorescence intensity in figure 3.8B. In the following 
experiment (figure 3.9A) it did have a significant increase in cell lengths but the R/G 
fluorescence intensity did not show any differences (figure 3.9B). These fluctuations 
might yet again be a function of the huge loss in viable cells, given that the range of 
viable cells at the end of ischemia/reperfusion was between 10.4±2.1% and 
23.0±2.9%. 
The 10nM HU210 concentration used in this project was also decided based on a 
dose response of HU210 treatment during ischemia, on survival parameters at the 
end of ischemia/reperfusion done by Dr. E Samodien. The mitochondrial viability 
(figure3.6B) showed that the HU210 administered during ischemia had a significantly 
(p ≤ 0.05) increased value ischemia (1.5±0.0) when compared to ischemia untreated 
(1.0±0.1), but this could not be seen in the following experiments (figures 3.8 and 
figures 3.9) for any of the parameters (hypercontracture, mitochondrial membrane 
potential and cell viability). This is yet again in contrast with the literature found for 
HU210 in ischemia/reperfusion (Krylatovet al, 2001). 
 
Absence of damage exacerbation with B1 stimulation during ischemia 
A dose range of 1uM, 10uM and 100uM dobutamine was administered during 
normoxia and ischemia and showed no effect on any of the survival parameters 
(figure 3.4). In view of this result a concentration of 10uM dobutamine was chosen 
given that 1uM dobutamine was used by Wang et al (2014) to pre-treat rats in vivo 
before ischemia/reperfusion. Incidentally in this study dobutamine exerted cardio 
protection in the form of reduced infarct size. On the other hand Pantos et al (2006) 
found that dobutamine treatment during reperfusion enhanced functional recovery. 
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One study that implicated b1AR in ischemia/reperfusion damage did not make use of 
dobutmine or any b-AR agonist, but instead used a b1AR antagonist to subtract 
b1AR stimulation during ischemia against a background of norepinephrine in the 
whole heart (Spear et al 2007). However, the absence of any enhancement of 
ischemic injury was confirmed in the laboratory by other lab colleagues in their 
studies, which shows consistency and confidence in the data. It is therefore possible 
that the ischemic insult exerted maximum damage, making it impossible for 
dobutamine to enhance hypercontracture or cell death. We decided not to use 1uM 
to determine if a higher concentration would elicit the damaging outcome as 
expected but still did not see any changes. 
Isoproterenol during normoxic treatments did not show a difference in the 
concentrations tested, and a decision was made to use the 100nM concentration as 
this is what literature suggests as well (Zhou et al, 2001;Leroy et al, 2011). The 
100nM isoproterenol administered during ischemia only showed a significant 
difference when compared to untreated ischemia, for mitochondrial membrane 
potential in figure3.6B, but not in  cell length and cell viability. The experiment in 
figure 3.9 did not produce the same results. Like with the dobutamine, this result was 
confirmed in the laboratory in the studies of other lab colleagues, and might also not 
enhance cell damage because maximum damage might have already been achieved 
with the harsh ischemic conditions used. Yet again in these experiments the average 
percentage viable cells for all ischemic treatments were 16.9±5.8% (figure 3.5C), 
10.5±2.8% (figure 3.6C) and 16.0±5.1% (figure 3.9C). 
 
In figure3.6D a screening experiment was done to measure the cAMP production at 
the basal level in the untreated cardiomyocytes. This showed low basal levels of 
cAMP and remained so even in the presence of PDE4 inhibition with rolipram. A 
slight increase by total PDE inhibition with IBMX was monitored but no statistical 
analysis was done due to a low n-value of 2. 100nM Isoproterenol did not indicate a 
production of cAMP but did however increased 16 fold when combined with PDE4 
inhibition (Iso + Rol) and 35 fold with total PDEs inhibition (Iso + IBMX). This shows 
that the absence of survival changes in the presence versus absence of these drugs 
is not due to faulty drugs.  
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No effect of Rolipram on cardiomyocytes 
For this project the 10uM rolipram concentration was chosen as literature also used 
10uM rolipram in their experiments (Bethke et al, 1992; Georget et al, 2003; De 
Arcangelis et al, 2008; Qvigstad et al, 2010; Beca et al, 2011; Leroy et al 2011; 
Parks et al, 2014). As most of these experiments were done with the cardiac tissue 
or whole heart perfusions at normal physiological functions. For the project we hoped 
to see a further damaging effect when rolipram was applied, this would have 
indicated a protective mechanism in which PDE4 does play a role during protection 
against ischemia. But the results would still determine whether PDE4 inhibtion during 
an ischeamic event would contribute to further damage or protection. Unfortunately 
rolipram did not show any differences during the normoxia treatments (figure 3.3). 
Even with rolipram ischemic pre-treatment and pertreatment combined, there was no 
effect on the poor cardiomyocyte survival (figure 3.3; 3.6; 3.7; 3.8 and 3.9) found. 
With all the treatments given and the combination therapy treatment of the different 
treatments with rolipram, only one treatment (10nM HU210 combined with rolipram) 
showed a significant decrease in cell hypercontracture (figure 3.8A), but this could 
not be replicated again with the following experiment (figure 3.9A). 
 The graph of R/G fluorescence ratio (figure3.6B) showed a significant increase with 
a p ≤ 0.01 in mitochondrial viability when 100nM Isoproterenol combined with 
rolipram during ischemia was compared to the ischemia untreated group. The  
separate treatments of isoproterenol and rolipram during ischemia did not show any 
differences when compared to ischemia untreated, but when combined during 
ischemia, isoproterenol and rolipram significantly (p ≤ 0.01) improved mitochondrial 
viability. This could not be supported by the following experiments in figures 3.8 and 
figures 3.9. 
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Chapter 5: Recommendations and conclusion 
Pitfalls in this study and recommendations for future work 
The ischemic conditions were considered successful in inducing sufficient 
ischemia/reperfusion damage because untreated ischemia/reperfusion consistently 
reduced cell length significantly to show hypercontracture and reduced cell survival 
percentages approximately 4 fold to 20%. Yet, all the cardio protective treatments 
failed to elicit protection while damage could not be enhanced by b1AR stimulation 
with dobutamine or isoproterenol. Similar results were found by another MSc student 
(Botha A) who could not consistently find protection with insulin and formoterol, while 
b1AR stimulation with dobutamine and isoproterenol failed to enhance 
ischemia/reperfusion injury (data not shown). Collectively this data might suggest 
that there may have been a fundamental flaw in the simulated ischemia/reperfusion 
model used, which might be the ischemic conditions that were too harsh for any of 
the drugs to alter survival or damage in the cardiomyocytes. 
The ischemic conditions of 3mM 2DG and 10mM SDT treatment for 20 minutes were 
chosen based on simulated ischemia/reperfusion times and doses optimized by an 
MSc student in the laboratory (Labuschagne SW, 2015), who found cardio protection 
with insulin, formoterol and BRL-37344 and no changes in survival parameters with 
isoproterenol and dobutamine (data not shown). The ischemic conditions might be 
dependent on the researcher, and should therefore be optimized for each 
researcher. Not all researchers will handle the cells in an identical manner, and this 
might result in different total numbers of cells remaining attached to the culture 
surface at the end of reperfusion. With more cells remaining behind at the end of the 
experiments for microscopy evaluation, a more accurate assessment can be made 
of the drug effects.  
The main rationale for keeping the ischemic doses and times identical for all 
students in the laboratory was so that all the work formed part of one main project 
that investigates the role PDEs in cardio protection and damage, which was thought, 
would make the data comparable. Instead all students did not consistently find the 
same data, except for the lack of effects with dobutamine and isoproterenol. Thus as 
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long as each researcher get to the final end point of an ischeamic event one should 
consider to optimize the protocol of mimicking the ischemia accordingly.  
It might have been more expedient to have used a shorter time of ischemia for the 
ischemic chemical conditions used in this thesis. Alternatively, given that SDT 
reduce oxygen levels in solution (Bright et al, 1992; Egar et al 2014), SDT rather 
than 2DG should be reduced and ischemia optimized for a longer duration. This 
would ensure that the development of pathology occur slower during ischemia, which 
could allow proper evaluation of the drugs tested here. SDT should specifically be 
considered, given that it is largely responsible for the ischemic effect due to its ability 
to reduce oxygen in solution (Bright et al, 1992; Egar et al 2014).  
Hypoxia should also be considered instead of chemical induced ischemia, given that 
hypoxia is more commonly used in the literature (Diaz et al, 2006), while only a few 
publications made use of SDT. Search terms with sodium dithionite+cardiomyocytes 
in Pubmed delivered only 7 publications, while an additional 2 were found with the 
search terms sodium hydrosulfite, while hypoxia+cardiomyocytes delivers 2200 
publications. A low frequency of publications on the use of SDT might indicate that it 
is not a method that works well, which might be the change in the potency of SDT 
over time from the time point that it is prepared in solution. The latter observation 
was made during the project, where SDT would rapidly bleach phenol red in the 
M199 based experimental buffer when freshly made SDT was added, while this 
bleaching effect occurred slower when SDT was used later in the day. Thus, it 
seems that SDT might be very unstable and its use from the point of preparation to 
use on the cells should preferably be kept constant in future experiments. Yet, if this 
drug is unstable it would be more appropriate to use hypoxia instead of simulated 
ischemia, especially because in a hypoxia model pathologies develop very slowly, 
normally over a time frame of hours (Kang et al, 2000). 
Interestingly, in experiments where cardiomyocytes were preloaded with fluo4 and 
JC-1 to measure intracellular calcium and MPTP opening respectively, these 
fluorescent labels were bleached at the end of ischemia (data not shown). This is 
similar to the bleaching effect that SDT has on phenol red in the M199 based 
experimental medium used, when SDT was add to prepare ischemic buffer. SDT 
therefore limits the use of fluorescent markers during ischemia, which prevents the 
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measurement of some critical markers such as intracellular calcium, pH and nitric 
oxide. In this regard, a model of hypoxia would also be more appropriate for the 
measure of these parameters given that the fluorescent labels should be preserved, 
given their use in hypoxia (Lu et al, 2010; Perry et al, 2011; Sun et al, 2004; Xiao et 
al, 2011). 
Looking at the fluorescence intensity results, it may appear to be inconsistent, 
possible reason for this might be due to the JC-1 staining. The red fluorescence of 
the stain on the cells fades quickly and is thus important to capture the images as 
quickly as possible. Our experiments were performed in sterile black costar 96-well 
plates. This means 96 photos needed to be taken, which takes time. This might be a 
possible reason for the inconsistencies found. Also the JC-1 stain is very light 
sensitive (precaution was used not to disrupt the staining) and it might not have been 
properly dissolved. This is possible explanations but every experiment was 
performed with caution not to alter the results obtained. 
For future research, it would be interesting to test PDE4’s role in ischemia by still 
investigating the cellular level (cardiomyocytes) through cardiomyocytes contraction 
and apoptosis, but cAMP measurements can also be taken, looking at the pH during 
ischemia as well as the calcium levels. Glucose uptake can also be measured. 
Finally this investigation can also look at whole heart perfusions with global and 
regional ischemia experiments. 
Conclusion 
Rolipram was used to inhibit PDE4 to determine whether a difference in survival 
parameters would occur when combined with b1AR, b2AR, b3AR, insulin, THC and 
HU210 signalling pathways. 10uM THC, 10nM HU210 and 100nM isoproterenol did 
indicate differences but could not be supported with follow up experiments. In this 
view, no difference in protective effects could be elicited, nor could pathology be 
worsened with any of the drug treatments. This is thought to be a consequence of 
the extremely harsh ischemic conditions used. For the final conclusion of this study: 
PDE4 may not be able to alter protection or damaging pathways in an isolated 
cardiomyocyte model of severe ischemia.   
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